Atlas Trials

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Clinical trial NCT07479797 · RECRUITING

Trial details

NCT number
NCT07479797
Sponsor
Kite, A Gilead Company
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed or Refractory Large B-cell Lymphoma
Start date
2026-05-22
Primary completion
2031-05-01
Enrollment
550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.